12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Prevenar 13: Phase III data

Pfizer reported data from an open-label Phase III trial 598 healthy children showing that Prevnar 13 met all study endpoints by demonstrating immunogenicity at 1 month post-vaccination and establishing a safety profile in children aged 5-17 years old regardless of prior vaccination with Prevnar ( PCV7), the pharma's vaccine containing 7 serotypes. Two age groups of children were enrolled in the trial - healthy children aged 5-10 years of age previously vaccinated with >=1 dose of PCV7 and...

Read the full 373 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >